Antimicrobial Susceptibility Testing Market - Global Forecasts to 2029

Table of Content

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 INCLUSIONS AND EXCLUSIONS 27
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 27
1.4 STAKEHOLDERS 28
1.5 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.2 RESEARCH DESIGN 30
2.2.1 SECONDARY RESEARCH 30
2.2.2 PRIMARY RESEARCH 32
2.2.2.1 Primary sources 33
2.2.2.2 Key industry insights 34
2.2.2.3 Breakdown of primaries 34
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 37
2.3.1.2 Approach 2: Customer-based market estimation 38
2.3.1.3 Approach 3: Top-down approach 39
2.3.1.4 Approach 4: Primary interviews 40
2.3.1.5 CAGR projections 41
2.4 DATA TRIANGULATION & MARKET BREAKDOWN 42
2.5 MARKET SHARE ASSESSMENT 43
2.6 STUDY ASSUMPTIONS 43
2.7 ASSUMPTIONS/MARKET FORECASTING METHODOLOGY 43
2.8 LIMITATIONS AND RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
?
4 PREMIUM INSIGHTS 49
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW 49
4.2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY REGION, 2024 VS. 2029 (USD MILLION) 50
4.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,
BY REGION AND END USER, 2023 (USD MILLION) 51
4.4 GEOGRAPHIC GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY
TESTING MARKET 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 54
5.2.1.1 Rising antimicrobial resistance 54
5.2.1.2 Advancements in diagnostic technologies 56
5.2.1.3 Expansion of clinical research applications 57
5.2.1.4 Rise in government initiatives 58
5.2.2 RESTRAINTS 58
5.2.2.1 High cost of automated instruments 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Emergence of rapid testing solutions 59
5.2.3.2 Integration with digital health technologies 60
5.2.4 CHALLENGES 61
5.2.4.1 Intricate regulatory landscape 61
5.3 INDUSTRY TRENDS 62
5.3.1 ISOTHERMAL MICROCALORIMETRY 62
5.3.2 FLUORESCENCE-ACTIVATED CELL SORTING 63
5.3.3 SMARTPHONE-BASED OPTICAL SPECTROSCOPY 63
5.3.4 MICROFLUIDICS AND MICRODROPLETS 63
5.4 ECOSYSTEM ANALYSIS 64
5.5 SUPPLY CHAIN ANALYSIS 65
5.5.1 PROMINENT COMPANIES 65
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES 65
5.5.3 END USERS 65
5.6 VALUE CHAIN ANALYSIS 66
5.7 PORTER’S FIVE FORCES ANALYSIS 68
5.7.1 THREAT OF NEW ENTRANTS 69
5.7.2 BARGAINING POWER OF SUPPLIERS 69
5.7.3 BARGAINING POWER OF BUYERS 69
5.7.4 THREAT OF SUBSTITUTES 69
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 69
?
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 70
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 70
5.8.2 BUYING CRITERIA 71
5.9 PATENT ANALYSIS 72
5.10 TRADE ANALYSIS 75
5.10.1 IMPORT DATA 75
5.10.2 EXPORT DATA 76
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 77
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.13 TECHNOLOGY ANALYSIS 78
5.13.1 KEY TECHNOLOGIES 79
5.13.1.1 PCR 79
5.13.1.2 Microfluidics and lab-on-a-chip 79
5.13.1.3 Synthetic antimicrobial peptides 79
5.13.2 COMPLIMENTARY TECHNOLOGIES 79
5.13.2.1 MALDI-TOF 79
5.13.3 ADJACENT TECHNOLOGIES 80
5.13.3.1 Nanotechnology 80
5.13.3.2 Nanomotion technology 80
5.13.3.3 Biochip technology 80
5.14 REGULATORY LANDSCAPE 81
5.14.1 NORTH AMERICA 81
5.14.1.1 US 81
5.14.1.2 Canada 82
5.14.2 EUROPE 82
5.14.3 ASIA PACIFIC 83
5.14.3.1 Japan 83
5.14.3.2 China 84
5.14.3.3 India 84
5.14.4 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
5.15 INVESTMENT AND FUNDING SCENARIO 87
5.16 PRICING ANALYSIS 88
5.16.1 AVERAGE SELLING PRICE, BY REGION 88
5.16.2 AVERAGE SELLING PRICE, BY KEY PLAYER 92
5.17 REIMBURSEMENT SCENARIO 92
5.18 UNMET NEEDS AND KEY PAIN POINTS 94
5.19 IMPACT OF AI/GEN AI ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 94
?
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT 96
6.1 INTRODUCTION 97
6.2 CONSUMABLES 97
6.2.1 CULTURE & GROWTH MEDIA 98
6.2.1.1 High utilization of disk diffusion and broth dilution methods
to drive market 98
6.2.2 SUSCEPTIBILITY TESTING DISKS 99
6.2.2.1 Low costs, ease of use to support adoption 99
6.2.3 MIC STRIPS 99
6.2.3.1 Accuracy, simplicity, and thorough results to drive usage 99
6.2.4 SUSCEPTIBILITY TESTING PLATES 100
6.2.4.1 Availability of specialized plates to drive market 100
6.3 LAB INSTRUMENTS 101
6.3.1 AUTOMATED LABORATORY INSTRUMENTS 102
6.3.1.1 Ongoing trend of laboratory automation to fuel segment growth 102
6.3.2 MOLECULAR DIAGNOSTICS SYSTEMS 103
6.3.2.1 Technological advancements in molecular diagnostics
to propel market 103
6.4 LAB DISPOSABLES 104
6.4.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED IN HOSPITALS TO DRIVE DEMAND 104
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 105
7.1 INTRODUCTION 106
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING 106
7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS 106
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING 107
7.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL DEMAND FOR TESTING 107
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING 109
7.4.1 RISING AWARENESS TO SUPPORT MARKET GROWTH 109
7.5 ANTIVIRAL SUSCEPTIBILITY TESTING 110
7.5.1 ADVANCEMENTS IN ANTIVIRAL SUSCEPTIBILITY TESTING TO ENHANCE PATIENT OUTCOMES 110
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD 111
8.1 INTRODUCTION 112
8.2 QUALITATIVE METHODS 112
8.2.1 AUTOMATED AST 113
8.2.1.1 Advancements and resistance patterns to drive use of automated instruments 113
8.2.2 DISK DIFFUSION 115
8.2.2.1 Simplicity, accuracy, and flexibility to support adoption 115
8.2.3 AGAR DILUTION 116
8.2.3.1 Time-consuming and labor-intensive nature to affect adoption 116
8.2.4 GENOTYPIC METHOD 117
8.2.4.1 Gold standard status to support greater adoption 117
8.3 QUANTITATIVE METHODS 118
8.3.1 ETEST METHOD 119
8.3.1.1 Etest to hold larger share of quantitative methods market 119
8.3.2 BROTH MACRODILUTION 120
8.3.2.1 Precision, simultaneous testing capability to drive market 120
9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
9.2 CLINICAL DIAGNOSTICS 123
9.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 123
9.3 DRUG DISCOVERY & DEVELOPMENT 124
9.3.1 EMPHASIS ON R&D AND INNOVATION TO SUPPORT DEMAND GROWTH 124
9.4 EPIDEMIOLOGY 125
9.4.1 NEED FOR BETTER UNDERSTANDING AND DECISION MAKING TO PROPEL ADOPTION 125
9.5 OTHER APPLICATIONS 126
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 127
10.1 INTRODUCTION 128
10.2 HOSPITALS & DIAGNOSTIC CENTERS 128
10.2.1 HOSPITALS & DIAGNOSTIC CENTERS TO HOLD LARGEST MARKET SHARE 128
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129
10.3.1 EMPHASIS ON PRODUCT DEVELOPMENT TO DRIVE MARKET 129
10.4 ACADEMIC & RESEARCH INSTITUTES 130
10.4.1 RISING R&D ACTIVITY AND SUPPORT FOR RESEARCH TO DRIVE MARKET 130
10.5 CLINICAL RESEARCH ORGANIZATIONS 132
10.5.1 EXPANSION OF CLINICAL TRIALS WORLDWIDE TO PROPEL MARKET GROWTH 132
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 133
11.1 INTRODUCTION 134
11.2 NORTH AMERICA 135
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 135
11.2.2 US 140
11.2.2.1 US to hold largest share of North American market 140
11.2.3 CANADA 142
11.2.3.1 Favorable government initiatives to drive market growth 142
?
11.3 EUROPE 144
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 144
11.3.2 GERMANY 149
11.3.2.1 Government initiatives for AMR to drive market 149
11.3.3 FRANCE 150
11.3.3.1 Focus on enhancing AMR surveillance to propel market 150
11.3.4 UK 152
11.3.4.1 New action plans for AMR to propel adoption 152
11.3.5 ITALY 153
11.3.5.1 Rising instances of AMR and high use of antibiotics to propel demand for testing 153
11.3.6 SPAIN 155
11.3.6.1 Rising AMR in gram-negative bacilli to drive market 155
11.3.7 REST OF EUROPE 157
11.4 ASIA PACIFIC 158
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 159
11.4.2 JAPAN 164
11.4.2.1 Industry-government collaborations for infectious disease management to support market growth 164
11.4.3 CHINA 166
11.4.3.1 Rising emphasis on AMR management to drive market 166
11.4.4 INDIA 168
11.4.4.1 Expanding government and industry efforts in clinical diagnostics to propel market growth 168
11.4.5 AUSTRALIA 170
11.4.5.1 Establishment and implementation of antimicrobial treatment guidelines to favor market growth 170
11.4.6 SOUTH KOREA 172
11.4.6.1 Need for rapid AMR detection to drive demand for automated AST systems 172
11.4.7 REST OF ASIA PACIFIC 173
11.5 LATIN AMERICA 175
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 175
11.5.2 BRAZIL 179
11.5.2.1 Rising emphasis on implementing AMR detection to drive market 179
11.5.3 MEXICO 181
11.5.3.1 Economic growth to support expansion of AST systems 181
11.5.4 REST OF LATIN AMERICA 182
11.6 MIDDLE EAST & AFRICA 183
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 184
11.6.2 GCC COUNTRIES 188
11.6.2.1 Healthcare infrastructural development initiatives to support growth 188
11.6.3 REST OF MIDDLE EAST & AFRICA 189
12 COMPETITIVE LANDSCAPE 191
12.1 OVERVIEW 191
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 191
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 192
12.3 REVENUE ANALYSIS 193
12.4 MARKET SHARE ANALYSIS, 2023 194
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 196
12.5.1 STARS 196
12.5.2 EMERGING LEADERS 196
12.5.3 PERVASIVE PLAYERS 196
12.5.4 PARTICIPANTS 196
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 198
12.5.5.1 Company footprint 198
12.5.5.2 Region footprint 199
12.5.5.3 Product footprint 200
12.5.5.4 Type footprint 201
12.5.5.5 Method footprint 202
12.5.5.6 Application footprint 203
12.5.5.7 End-user footprint 204
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 205
12.6.1 PROGRESSIVE COMPANIES 205
12.6.2 RESPONSIVE COMPANIES 205
12.6.3 DYNAMIC COMPANIES 205
12.6.4 STARTING BLOCKS 205
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 207
12.7 VALUATION & FINANCIAL METRICS 209
12.7.1 FINANCIAL METRICS 209
12.7.2 COMPANY VALUATION 209
12.8 BRAND/PRODUCT COMPARISON 210
12.9 COMPETITIVE SCENARIO 211
12.9.1 PRODUCT LAUNCHES & APPROVALS 211
12.9.2 DEALS 212
13 COMPANY PROFILES 213
13.1 KEY PLAYERS 213
13.1.1 BIOM?RIEUX SA 213
13.1.1.1 Business overview 213
13.1.1.2 Products offered 214
13.1.1.3 Recent developments 216
13.1.1.3.1 Product launches & approvals 216
13.1.1.3.2 Deals 217
13.1.1.4 MnM view 217
13.1.1.4.1 Right to win 217
13.1.1.4.2 Strategic choices 217
13.1.1.4.3 Weaknesses & competitive threats 217
13.1.2 BECTON, DICKINSON AND COMPANY 218
13.1.2.1 Business overview 218
13.1.2.2 Products offered 220
13.1.2.3 Recent developments 221
13.1.2.3.1 Deals 221
13.1.2.3.2 Other developments 221
13.1.2.4 MnM view 221
13.1.2.4.1 Right to win 221
13.1.2.4.2 Strategic choices 222
13.1.2.4.3 Weaknesses and competitive threats 222
13.1.3 THERMO FISHER SCIENTIFIC INC. 223
13.1.3.1 Business overview 223
13.1.3.2 Products offered 224
13.1.3.3 Recent developments 226
13.1.3.3.1 Product launches & approvals 226
13.1.3.3.2 Deals 226
13.1.3.4 MnM view 227
13.1.3.4.1 Right to win 227
13.1.3.4.2 Strategic choices 227
13.1.3.4.3 Weaknesses and competitive threats 227
13.1.4 DANAHER CORPORATION 228
13.1.4.1 Business overview 228
13.1.4.2 Products offered 230
13.1.4.3 Recent developments 231
13.1.4.3.1 Product launches & approvals 231
13.1.4.3.2 Deals 232
13.1.4.4 MnM view 233
13.1.4.4.1 Right to win 233
13.1.4.4.2 Strategic choices 233
13.1.4.4.3 Weaknesses and competitive threats 233
13.1.5 BIO-RAD LABORATORIES, INC. 234
13.1.5.1 Business overview 234
13.1.5.2 Products offered 235
13.1.5.2.1 Deals 236
13.1.5.3 MnM view 236
13.1.5.3.1 Right to win 236
13.1.5.3.2 Strategic choices 236
13.1.5.3.3 Weaknesses and competitive threats 236
13.1.6 BRUKER 237
13.1.6.1 Business overview 237
13.1.6.2 Products offered 239
13.1.6.3 Recent developments 241
13.1.6.3.1 Product launches & approvals 241
13.1.6.3.2 Deals 241
13.1.7 ROCHE DIAGNOSTICS 242
13.1.7.1 Business overview 242
13.1.7.2 Products offered 243
13.1.7.3 Recent developments 245
13.1.7.3.1 Product launches & approvals 245
13.1.7.3.2 Deals 246
13.1.8 MERCK KGAA 247
13.1.8.1 Business overview 247
13.1.8.2 Products offered 248
13.1.8.3 Recent developments 249
13.1.8.3.1 Deals 249
13.1.9 ACCELERATE DIAGNOSTICS, INC. 250
13.1.9.1 Business overview 250
13.1.9.2 Products offered 251
13.1.9.3 Recent developments 252
13.1.9.3.1 Product launches & approvals 252
13.1.9.3.2 Deals 252
13.1.9.3.3 Other developments 252
13.1.10 HIMEDIA LABORATORIES 253
13.1.10.1 Business overview 253
13.1.10.2 Products offered 254
13.1.11 LIOFILCHEM S.R.L. 255
13.1.11.1 Business overview 255
13.1.11.2 Products offered 255
13.1.12 ALIFAX S.R.L. 258
13.1.12.1 Business overview 258
13.1.12.2 Products offered 258
13.1.13 CREATIVE DIAGNOSTICS 259
13.1.13.1 Business overview 259
13.1.13.2 Products offered 260
13.1.14 SYNBIOSIS 261
13.1.14.1 Business overview 261
13.1.14.2 Products offered 262
13.1.15 BIOANALYSE 263
13.1.15.1 Business overview 263
13.1.15.2 Products offered 263
13.2 OTHER KEY PLAYERS 264
13.2.1 ZHUHAI DL BIOTECH CO., LTD. 264
13.2.2 ELITECHGROUP 265
13.2.3 MAST GROUP LTD. 267
13.2.4 CONDALAB 268
13.2.5 GENEFLUIDICS, INC. 269
13.2.6 BIOTRON HEALTHCARE 269
13.2.7 INVIVOGEN 270
13.2.8 MP BIOMEDICALS 271
13.2.9 QUANTAMATRIX INC. 271
13.2.10 SYSMEX EUROPE SE 272
13.2.11 COPAN DIAGNOSTICS INC. 272
13.2.12 ERBA DIAGNOSTICS MANNHEIM GMBH 273
14 APPENDIX 274
14.1 DISCUSSION GUIDE 274
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279
14.3 CUSTOMIZATION OPTIONS 281
14.4 RELATED REPORTS 281
14.5 AUTHOR DETAILS 282

List of Figures

FIGURE 1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION 26
FIGURE 2 RESEARCH DESIGN 29
FIGURE 3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: RESEARCH DESIGN 30
FIGURE 4 KEY DATA FROM SECONDARY SOURCES 32
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATION, AND REGION 35
FIGURE 7 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:
APPROACH 1 (COMPANY REVENUE ESTIMATION) 37
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:
BOTTOM-UP APPROACH 38
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:
END-USER APPROACH 39
FIGURE 11 TOP-DOWN APPROACH 40
FIGURE 12 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 41
FIGURE 13 DATA TRIANGULATION METHODOLOGY 42
FIGURE 14 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2024 VS. 2029 (USD MILLION) 45
FIGURE 15 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2024 VS. 2029 (USD MILLION) 46
FIGURE 16 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2024 VS. 2029 (USD MILLION) 46
FIGURE 17 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2024 VS. 2029 (USD MILLION) 47
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 48
FIGURE 19 INCREASING RESEARCH ACTIVITIES AND ADVANCEMENTS IN AUTOMATED & MOLECULAR DIAGNOSTIC INSTRUMENTS TO DRIVE MARKET 49
FIGURE 20 NORTH AMERICAN MARKET TO HOLD LARGEST MARKET SHARE 50
FIGURE 21 HOSPITALS & DIAGNOSTIC CENTERS SEGMENT ACCOUNTED
FOR LARGEST MARKET SHARE IN 2023 51
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
FIGURE 23 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 24 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ECOSYSTEM ANALYSIS 64
FIGURE 25 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: SUPPLY CHAIN ANALYSIS 66
FIGURE 26 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS 67
FIGURE 27 ANTIMICROBIAL SUSCEPTIBILITY TESTING: PORTER’S FIVE FORCES 68
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS 70
FIGURE 29 KEY BUYING CRITERIA, BY END USER 71
FIGURE 30 PATENT ANALYSIS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (JANUARY 2013–DECEMBER 2023) 72
?
FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS 78
FIGURE 32 INVESTMENT AND FUNDING SCENARIO, 2019–2023 87
FIGURE 33 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 88
FIGURE 34 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION) 88
FIGURE 35 AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION, 2021–2023 (USD) 90
FIGURE 36 AVERAGE SELLING PRICE FOR TOP 3 APPLICATIONS, BY KEY PLAYER 92
FIGURE 37 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 136
FIGURE 38 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT 160
FIGURE 39 CHINA: INCIDENCE OF INFECTIOUS DISEASES, 2023 167
FIGURE 40 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET, 2019–2023 (USD MILLION) 193
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET (2023) 194
FIGURE 42 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 197
FIGURE 43 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY FOOTPRINT 198
FIGURE 44 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 206
FIGURE 45 EV/EBITDA OF KEY VENDORS 209
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 209
FIGURE 47 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET:
BRAND/PRODUCT COMPARATIVE ANALYSIS 210
FIGURE 48 BIOM?RIEUX: COMPANY SNAPSHOT (2023) 214
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 219
FIGURE 50 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 224
FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT 229
FIGURE 52 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 235
FIGURE 53 BRUKER: COMPANY SNAPSHOT 238
FIGURE 54 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 243
FIGURE 55 MERCK: COMPANY SNAPSHOT 248
FIGURE 56 ACCELERATE DIAGNOSTICS: COMPANY SNAPSHOT 251

List of Tables

TABLE 1 ANTIMICROBIAL SUSCEPTIBILITY TESTINGMARKET: INCLUSIONS & EXCLUSIONS 27
TABLE 2 LIMITATIONS AND ASSOCIATED RISKS 44
TABLE 3 MITIGATION OF ANTIMICROBIAL RESISTANCE 55
TABLE 4 COMPARISON OF ANTIMICROBIAL SUSCEPTIBILITY TESTING AUTOMATED
PRODUCT PRICING 59
TABLE 5 DISCREPANCIES BETWEEN FDA-APPROVED AST CRITERIA AND CDC-IDENTIFIED ANTIMICROBIAL RESISTANCE THREATS 61
TABLE 6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ROLE OF COMPANIES
IN ECOSYSTEM 64
TABLE 7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: IMPACT OF PORTER’S
FIVE FORCES 68
TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
TOP FOUR END USERS (%) 70
TABLE 9 KEY BUYING CRITERIA, BY END USER 71
TABLE 10 LIST OF MAJOR PATENT INNOVATIONS AND PATENT REGISTRATIONS, 2022–2024 73
TABLE 11 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019–2023 (USD THOUSAND) 75
TABLE 12 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019–2023 (USD THOUSAND) 76
TABLE 13 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 77
TABLE 14 US FDA: MEDICAL DEVICE CLASSIFICATION 81
TABLE 15 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 82
TABLE 16 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 82
TABLE 17 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS
AND MEDICAL DEVICES AGENCY 83
TABLE 18 CHINA: CLASSIFICATION OF MEDICAL DEVICES 84
TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 85
TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 85
TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 86
TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 86
TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 24 AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION 2021–2023 (USD THOUSAND) 90
TABLE 25 AVERAGE SELLING PRICE OF TOP 3 APPLICATIONS, BY KEY PLAYER, 2023 (USD) 92
TABLE 26 US: MAJOR CPT CODES ASSOCIATED WITH AST, 2023 93
TABLE 27 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: CURRENT UNMET NEEDS 94
TABLE 28 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 97
TABLE 29 ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 97
TABLE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY REGION, 2022–2029 (USD MILLION) 98
TABLE 31 CULTURE & GROWTH MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 32 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 33 MIC STRIPS MARKET, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 34 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION 2022–2029 (USD MILLION) 100
TABLE 35 ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 101
TABLE 36 ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY REGION, 2022–2029 (USD MILLION) 101
TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET BY REGION, 2022–2029 (USD MILLION) 103
TABLE 38 MOLECULAR DIAGNOSTICS SYSTEMS MARKET BY REGION, 2022–2029 (USD MILLION) 103
TABLE 39 LAB DISPOSABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 40 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 106
TABLE 41 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 107
TABLE 42 US: DEATHS FROM FUNGAL DISEASES, 2021 108
TABLE 43 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 108
TABLE 44 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 109
TABLE 45 ANTIVIRAL SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 110
TABLE 46 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 112
TABLE 47 QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET BY TYPE, 2022–2029 (USD MILLION) 113
TABLE 48 QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET BY REGION, 2022–2029 (USD MILLION) 113
TABLE 49 AVAILABLE AND EMERGING AUTOMATED AST TECHNOLOGIES 114
TABLE 50 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 115
TABLE 51 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION BY REGION, 2022–2029 (USD MILLION) 116
TABLE 52 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AGAR DILUTION BY REGION, 2022–2029 (USD MILLION) 117
TABLE 53 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR GENOTYPIC METHOD BY REGION, 2022–2029 (USD MILLION) 118
TABLE 54 QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET BY TYPE, 2022–2029 (USD MILLION) 118
TABLE 55 QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET BY REGION, 2022–2029 (USD MILLION) 119
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST METHOD BY REGION, 2022–2029 (USD MILLION) 120
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
FOR BROTH MACRODILUTION, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 122
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 60 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY
& DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 61 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY BY REGION, 2022–2029 (USD MILLION) 125
TABLE 62 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS BY REGION, 2022–2029 (USD MILLION) 126
TABLE 63 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 128
TABLE 64 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS &
DIAGNOSTIC CENTERS, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 68 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 2022–2029 (USD MILLION) 134
TABLE 69 NORTH AMERICA: MACROINDICATORS 135
TABLE 70 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 71 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 137
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 137
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 138
TABLE 74 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 138
TABLE 75 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 138
TABLE 76 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 139
TABLE 77 NORTH AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 139
TABLE 78 NORTH AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 139
TABLE 79 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 140
TABLE 80 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 141
TABLE 81 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 141
TABLE 82 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 83 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 143
TABLE 84 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 143
TABLE 85 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 143
TABLE 86 EUROPE: MACROINDICATORS 145
TABLE 87 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 88 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 146
TABLE 89 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 146
TABLE 90 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 146
TABLE 91 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 147
TABLE 92 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 147
TABLE 93 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 147
TABLE 94 EUROPE: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 95 EUROPE: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 96 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 148
TABLE 97 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 149
TABLE 98 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 99 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 100 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 151
TABLE 101 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 102 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 103 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 152
TABLE 104 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 105 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 106 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 154
TABLE 107 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 108 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 155
TABLE 109 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 156
TABLE 110 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 111 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 112 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 157
TABLE 113 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
TABLE 114 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
TABLE 115 ASIA PACIFIC: MACROINDICATORS 159
TABLE 116 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 117 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 161
TABLE 118 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 119 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 120 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 121 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 163
TABLE 122 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 163
TABLE 123 ASIA PACIFIC: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 124 ASIA PACIFIC: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 125 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 164
TABLE 126 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 165
TABLE 127 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 128 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 129 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 167
TABLE 130 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 131 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 132 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 169
TABLE 133 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 134 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 135 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 171
TABLE 136 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 137 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 138 SOUTH KOREA: LIST OF CONFERENCES ON ANTIMICROBIAL ACTIVITY, 2024 172
TABLE 139 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 172
TABLE 140 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 141 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 142 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 174
TABLE 143 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 144 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 145 LATIN AMERICA: MACROINDICATORS 175
TABLE 146 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 147 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 176
TABLE 148 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 149 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 150 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 151 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 177
TABLE 152 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 178
TABLE 153 LATIN AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 154 LATIN AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 155 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 179
TABLE 156 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 180
TABLE 157 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 158 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 159 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 181
TABLE 160 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 161 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 162 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 182
TABLE 163 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 164 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 165 MIDDLE EAST & AFRICA: MACROINDICATORS 184
TABLE 166 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY REGION, 2022–2029 (USD MILLION) 184
TABLE 167 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 185
TABLE 168 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 169 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 170 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 171 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY APPLICATION, 2022–2029 (USD MILLION) 186
TABLE 172 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY METHOD, 2022–2029 (USD MILLION) 186
TABLE 173 MIDDLE EAST & AFRICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 174 MIDDLE EAST & AFRICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 175 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY END USER, 2022–2029 (USD MILLION) 187
TABLE 176 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET BY PRODUCT, 2022–2029 (USD MILLION) 188
TABLE 177 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 178 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 179 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 190
TABLE 180 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 181 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 182 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS 192
TABLE 183 ANTIMICROBIAL SUSCEPTIBILITY MARKET: DEGREE OF COMPETITION 194
TABLE 184 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: REGION FOOTPRINT 199
TABLE 185 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT FOOTPRINT 200
TABLE 186 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: TYPE FOOTPRINT 201
TABLE 187 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: METHOD FOOTPRINT 202
TABLE 188 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: APPLICATION FOOTPRINT 203
TABLE 189 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: END-USER FOOTPRINT 204
TABLE 190 ANTIMICROBIAL SUSCEPTIBILITY MARKET: FRANCE DETAILED LIST OF KEY STARTUP/SME PLAYERS 207
?
TABLE 191 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS 208
TABLE 192 ANTIMICROBIAL SUSCEPTIBILITY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– SEPTEMBER 2024 211
TABLE 193 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET:
DEALS, JANUARY 2021– SEPTEMBER 2024 212
TABLE 194 BIOM?RIEUX: COMPANY OVERVIEW 213
TABLE 195 BIOM?RIEUX: PRODUCTS OFFERED 214
TABLE 196 BIOM?RIEUX: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–SEPTEMBER 2024 216
TABLE 197 BIOM?RIEUX: DEALS, JANUARY 2021–SEPTEMBER 2024 217
TABLE 198 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 218
TABLE 199 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 220
TABLE 200 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–SEPTEMBER 2024 221
TABLE 201 BECTON, DICKINSON AND COMPANY OTHER DEVELOPMENTS JANUARY 2021–SEPTEMBER 2024 221
TABLE 202 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 223
TABLE 203 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 224
TABLE 204 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024 226
TABLE 205 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–SEPTEMBER 2024 226
TABLE 206 DANAHER CORPORATION: COMPANY OVERVIEW 228
TABLE 207 DANAHER CORPORATION PRODUCTS OFFERED 230
TABLE 208 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–SEPTEMBER 2024 231
TABLE 209 DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024 232
TABLE 210 BIO-RAD LABORATORIES: COMPANY OVERVIEW 234
TABLE 211 BIO-RAD LABORATORIES: PRODUCTS OFFERED 235
TABLE 212 BIO-RAD LABORATORIES: DEALS, JANUARY 2021–SEPTEMBER 2024 236
TABLE 213 BRUKER: COMPANY OVERVIEW 237
TABLE 214 BRUKER: PRODUCTS OFFERED 239
TABLE 215 BRUKER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024 241
TABLE 216 BRUKER: DEALS, JANUARY 2021–SEPTEMBER 2024 241
TABLE 217 ROCHE DIAGNOSTICS: COMPANY OVERVIEW 242
TABLE 218 ROCHE DIAGNOSTICS PRODUCTS OFFERED 243
TABLE 219 ROCHE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–SEPTEMBER 2024 245
TABLE 220 ROCHE DIAGNOSTICS: DEALS, JANUARY 2021–SEPTEMBER 2024 246
TABLE 221 MERCK: COMPANY OVERVIEW 247
TABLE 222 MERCK: PRODUCTS OFFERED 248
TABLE 223 MERCK: DEALS, JANUARY 2021–SEPTEMBER 2024 249
TABLE 224 ACCELERATE DIAGNOSTICS: COMPANY OVERVIEW 250
TABLE 225 ACCELERATE DIAGNOSTICS: PRODUCTS OFFERED 251
TABLE 226 ACCELERATE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–SEPTEMBER 2024 252
?
TABLE 227 ACCELERATE DIAGNOSTICS: DEALS, JANUARY 2021–SEPTEMBER 2024 252
TABLE 228 ACCELERATE DIAGNOSTICS: OTHER DEVELOPMENTS JANUARY 2021–SEPTEMBER 2024 252
TABLE 229 HIMEDIA LABORATORIES: COMPANY OVERVIEW 253
TABLE 230 HIMEDIA LABORATORIES: PRODUCTS OFFERED 254
TABLE 231 LIOFILCHEM: COMPANY OVERVIEW 255
TABLE 232 LIOFILCHEM: PRODUCTS OFFERED 255
TABLE 233 ALIFAX: COMPANY OVERVIEW 258
TABLE 234 ALIFAX: PRODUCTS OFFERED 258
TABLE 235 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 259
TABLE 236 CREATIVE DIAGNOSTICS: PRODUCTS OFFERED 260
TABLE 237 SYNBIOSIS: COMPANY OVERVIEW 261
TABLE 238 SYNBIOSIS: PRODUCTS OFFERED 262
TABLE 239 BIOANALYSE: COMPANY OVERVIEW 263
TABLE 240 BIOANALYSE: PRODUCTS OFFERED 263